NEW YORK, Sept. 7, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that the Company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the second cohort, who, in keeping with trial protocol, will be injected with two times higher activity of the Company’s investigational new drug Actimab-A.
“This is a significant milestone for our company,” commented Jack Talley, CEO of Actinium Pharmaceuticals. “Our program is now advancing rapidly, offering new hope for patients who were until now generally considered untreatable, as additional leading cancer treatment centers continue to join our trial.”
The trial is a prospective, open-label study, designed to determine the safety and efficacy of Actimab-A in newly diagnosed AML patients who cannot tolerate current high dose chemotherapeutic regimens.
Mr. Talley added, “Acute myeloid leukemia in patients over the age of 60 is a serious unmet need and we are eager to make this treatment available to patients.”
Actimab-A is being developed using Company’s proprietary patented APIT technology and it consists of the monoclonal antibody Lintuzumab used to guide the alpha emitting radioisotope actinium 225 to malignant cells.
About actinium 225
Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first demonstrated by Dr. David Scheinberg at Memorial Sloan Kettering Cancer Center.
About Lintuzumab (HuM195)
Lintuzumab is a monoclonal antibody that targets CD33, found on myeloid leukemia cells. It is the humanized version of M195, the antibody initially developed by Dr. David Scheinberg of Memorial Sloan Kettering Cancer Center.
Acute Myeloid Leukemia is the most difficult to treat form of leukemia. The majority of patients do not qualify for the commonly used chemotherapy regimen and their median survival following diagnosis is about 2 months without treatment.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a Newark, New Jersey based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.
For more information:
Visit our web site www.actiniumpharmaceuticals.comor contact:
Media:
Dennis S. Dobson Jr., 203-258-0159
Email: dsdobson@optonline.com
www.dobsonmediagroup.com
Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel: (646) 459-4201
E-mail: actimaba@actiniumpharmaceuticals.com
Investors:
Jeff Ramson
ProActive Capital Group, LLC
Tel: (646) 863-6341
E-mail: jramson@proactivecrg.com
www.proactivecrg.com
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
E-mail: dcicic@actiniumpharmaceuticals.com
SOURCE Actinium Pharmaceuticals, Inc.
